LY2157299
Phase 2Small molecule
Eli LillyLY2157299 is one of 58 small molecule programs targeting Rectal Cancer. It is currently in Phase 2.
2
Indications
10
Total Trials
2
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antiandrogen Therapy
UUniversity of Washington
Phase 3
Xaluritamig
AmgenPhase 3
Radium-223
BayerPhase 3
Perflutren Lipid Microspheres
SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3
AAA817
NovartisPhase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
LY2157299
Eli LillyPhase 2
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignant Glioma2 trials
Hepatocellular Carcinoma2 trials
Pancreatic Cancer1 trial
3 more indications
Hepatocellular Cancer1 trial
Prostate Cancer1 trial
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02452008·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY2157299. EMBL-EBI & Wellcome Sanger Institute.
- [4]